MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/tcr-2024-2688

Медицинская библиотека · Translational cancer research · 2025

Carfilzomib plus pomalidomide and dexamethasone as salvage therapy in patients with relapsed or refractory multiple myeloma in China: a retrospective study.

Xiao Xibin, Shao Yanping, Li Xian, Jiang Huawei, Jiang Wei, Chen Panpan, Xie Jing, Qian Wenbin

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Regimens based on carfilzomib have shown significant improvement in survival for relapsed or refractory multiple myeloma (RRMM), but the combination of carfilzomib, pomalidomide and dexamethasone (KPd) has been scarcely investigated in China. This study aimed to evaluate the efficacy and safety of KPd regimen in Chinese patients with RRMM.

METHODS

Thirty-eight patients who had experienced one or more lines of therapy followed by the KPd regimen were retrospectively enrolled. After 4 cycles, the investigator switched eligible patients to maintenance therapy. The primary outcome was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS) and overall survival (OS). Adverse events (AEs) were also observed.

RESULTS

After 4 cycles of the KPd regimen, 23.7% of patients (9/38) achieved a complete response (CR), 42.1% (16/38) for very good partial response (VGPR), and 21.1% (8/38) for partial response (PR). The ORR was 86.8%. Of 33 patients who underwent maintenance therapy, 21 were administered the KPd regimen and 6 received daratumumab. The median PFS was 13.4 months and the median OS was not reached. Each patient experienced at least 2 AEs, mainly, neutropenia and anemia. Only 3 patients experienced Grade 3 AEs, and none of the other AEs was higher than Grade 2. No patient reported having experienced Grades 4-5 AEs.

CONCLUSIONS

The KPd regimen showed encouraging activity and manageable toxicity for RRMM patients in China.

Для цитирования: Xiao Xibin, Shao Yanping, Li Xian, Jiang Huawei, Jiang Wei, Chen Panpan, Xie Jing, Qian Wenbin. Carfilzomib plus pomalidomide and dexamethasone as salvage therapy in patients with relapsed or refractory multiple myeloma in China: a retrospective study.. Translational cancer research. 2025. DOI: 10.21037/tcr-2024-2688.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.